{
  "trial_id": "NCT00112827",
  "overall_assessment": "likely_ineligible",
  "inclusion": [],
  "exclusion": [
    {
      "criterion": "Inability to lie supine in a full body cast for approximately 30 minutes",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Previous radiation therapy to more than 20% of bone marrow containing areas, or to any area",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Patients must be fully aware of the teratogenic potential of thalidomide and agree to fully comply with the mandated guidelines regarding contraception as stated in the informed consent and the patient warning document attached to the consent form",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Women of childbearing potential must have a negative pregnancy test performed within 24 hours prior to beginning thalidomide, except for woman who have been postmenopausal for at least 2 years, or underwent hysterectomy",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Use of effective means of contraceptive should be started at least 2 weeks prior to initiating thalidomide",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "Patient has multiple myeloma with systemic amyloidosis and is on hemodialysis, which may make it difficult for her to comply with the trial's requirements.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT00112827",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}